Overview

Benazepril HCl 40 mg Tablets, Fasting

Status:
Completed

Trial end date:
2001-03-01

Target enrollment:

Participant gender:

Summary

The objective of this randomized, single-dose, two-way crossover evaluation is to compare the oral bioavailability of a test benazepril HCl formulation (TEVA Pharmaceutical Industries Ltd.) to an equivalent oral dose of the commercially available benazepril HCl (Lotensin®, Novartis Pharmaceuticals Corporation) in a test population of 40 adults under fasting conditions.

Phase:

Phase 1

Details

Lead Sponsor:

Teva Pharmaceuticals USA

Treatments:

Benazepril